3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 1
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Conditions
Melanoma
55
Neoplasm Metastasis
17
Carcinoma, Renal Cell
15
Carcinoma, Non-Small-Cell Lung
15
Neoplasms
14
Pancreatic Neoplasms
11
Uveal Melanoma
10
Prostatic Neoplasms
10
Leukemia, Myeloid, Acute
9
Squamous Cell Carcinoma of Head and Neck
7
Sarcoma
7
Myelodysplastic Syndromes
7
Lymphoma
7
Lung Neoplasms
7
Leukemia, Lymphocytic, Chronic, B-Cell
7
Colorectal Neoplasms
7
Carcinoma, Hepatocellular
7
Precursor Cell Lymphoblastic Leukemia-Lymphoma
6
Carcinoma, Transitional Cell
6
Breast Neoplasms
6
Triple Negative Breast Neoplasms
5
Small Cell Lung Carcinoma
5
Recurrence
5
Myeloproliferative Disorders
5
Multiple Myeloma
5
Lymphoma, Non-Hodgkin
5
Hematologic Neoplasms
5
Glioblastoma
5
Urinary Bladder Neoplasms
4
Ovarian Neoplasms
4
Interventions
Fluorouracil
11
Gemcitabine
8
pembrolizumab
7
Leucovorin
7
Irinotecan
7
Paclitaxel
6
Oxaliplatin
5
Carboplatin
5
130-nm albumin-bound paclitaxel
5
Nivolumab
4
Cisplatin
4
Albumin-Bound Paclitaxel
4
Taxes
3
Ramucirumab
3
Radiosurgery
3
Pemetrexed
3
Docetaxel
3
Capecitabine
3
Bevacizumab
3
vandetanib
2
spartalizumab
2
selinexor
2
osimertinib
2
folfirinox
2
Radiation
2
Cyclophosphamide
2
zolbetuximab
1
trastuzumab deruxtecan
1
trametinib
1
tofacitinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Adenocarcinoma
×
Ipilimumab
×
Clear all
NCT04315155
2020-10-28
BENEFIT
University of Utah
Phase 1
Withdrawn